Tofflon plans to invest 200 million yuan to participate in the establishment of the Shanghai Biopharmaceutical M&A Fund
I'm LongbridgeAI, I can summarize articles.Tofflon announced that it will invest 200 million yuan to participate in the establishment of the Shanghai Biopharmaceutical M&A Fund, aiming to promote the company's long-term development and improve the layout of the pharmaceutical equipment industry. The total subscribed capital of the fund is 5.01 billion yuan, with Tofflon holding a 3.99% stake as a limited partner. The fund will focus on key areas such as biopharmaceuticals, innovative traditional Chinese medicine, and high-end medical devices, leveraging the resource advantages of professional investment institutions to expand client resources in the biopharmaceutical industry
According to the Zhitong Finance APP, Tofflon (300171.SZ) announced that in order to promote the company's long-term development, fully leverage the resource advantages of professional investment institutions, further improve the industrial layout of the pharmaceutical equipment sector, and achieve the leading, driving, and connecting roles of the industrial chain, the company plans to jointly invest with Shanghai Guotou Xian Dao Biomedical Private Equity Investment Fund Partnership (Limited Partnership), Shanghai Pharmaceuticals Holding Co., Ltd., Shanghai Junshi Biosciences Co., Ltd., Shanghai Meixin Health Technology Group Co., Ltd., New China Life Insurance Co., Ltd., ICBC-AXA Life Insurance Co., Ltd., Shanghai Pudong Leading Area Investment Center (Limited Partnership), Shanghai Zhangjiang Technology Venture Capital Co., Ltd., Shanghai Xingjia Phase II Private Equity Investment Fund Partnership (Limited Partnership), Shanghai Malu Economic Development Co., Ltd., Chengdu Jiaozi Zhongying Innovation Development Fund Partnership (Limited Partnership), Shanghai Shangshi Capital Management Co., Ltd. (referred to as "Shangshi Capital", "Manager", "GP1"), Shanghai Biomedical M&A Equity Investment Fund Management Co., Ltd. (tentative name, final name subject to industrial and commercial registration approval, referred to as "M&A Fund Management Company", "GP2"), and Shanghai Lubu Ka Enterprise Management Consulting Partnership (Limited Partnership) to establish the Shanghai Biomedical M&A Equity Investment Partnership (Limited Partnership) (tentative name, final name subject to industrial and commercial registration approval, referred to as "Partnership", "Shanghai Biomedical M&A Fund", "Fund").
At the time of the fund's establishment, all partners plan to contribute a total of RMB 5.01 billion, with the company intending to contribute RMB 200 million as a limited partner, accounting for 3.99% of the total contribution. The fund will mainly focus on the following investment directions: key areas of the Shanghai biomedical industry development plan, including biopharmaceuticals, innovative traditional Chinese medicine, high-end medical devices, advanced equipment and materials, new services, and innovative business formats.
This collaboration with professional investment institutions to establish the fund aims to leverage their resources and advantages in the field of equity investment, which will help the company expand its channels for top customer resources in the biomedical industry, generating positive synergy effects; on the other hand, it will benefit the company's business layout in the biomedical sector, further complementing and strengthening the company's product chain and enhancing its overall market competitiveness